Virax Biolabs (NASDAQ:VRAX) stock is on the rise Thursday as investors react to the news on an extension from the Nasdaq Exchange.
According to a press release from the diagnostics test kits maker, the Nasdaq is giving it an additional 180 days to regain compliance. The company is currently trying to boost the price of its stock back above $1 per share to avoid delisting.
This marks the second set of 180 days that Virax Biolabs has been given to regain compliance. The first was on Jan. 30, 2023. With this new notice, the company now has until Jan. 29, 2024, to regain compliance with the Nasdaq’s listing standards.
In order to regain compliance, Virax Biolabs has to do more than just get VRAX stock back above $1 per share. It has to do this and maintain a share price above that trading minimum for 10 consecutive business days.
How Will VRAX Stock Regain Compliance?
Virax Biolabs hasn’t laid out plans for how it will boost its share price above the $1 minimum. One option the company may take is a reverse stock split. This would consolidate shares to increase their price without adjusting the company’s market capitalization.
Trading of VRAX stock is light today, with some 29,000 shares on the move. That’s still a ways off from its daily average trading volume of about 259,000 shares. Even so, the stock is up 1.1% as of Thursday morning.
Investors can keep reading for even more of the most recent stock market news today.
We’ve got all of the biggest stock stories that traders need to know about on Thursday! A few examples include why shares of Roku (NASDAQ:ROKU), Aravive (NASDAQ:ARAV), and Vicarious Surgical (NYSE:RBOT) are in the news today. You can catch up on all of this stock market news by checking out the links below!
More Stock Market News for Thursday
- ROKU Stock Alert: Why Citi Just Downgraded Roku Shares
- Why Is Vicarious Surgical (RBOT) Stock Down 41% Today?
- Why Is Aravive (ARAV) Stock Down 58% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.